Oppenheimer Comments on Icosavax, Inc.’s Q1 2023 Earnings (NASDAQ:ICVX)

Posted by Defense World Staff on Apr 28th, 2023

Icosavax, Inc. (NASDAQ:ICVX – Get Rating) – Equities researchers at Oppenheimer issued their Q1 2023 earnings per share (EPS) estimates for Icosavax in a report issued on Tuesday, April 25th. Oppenheimer analyst H. Singh forecasts that the company will post earnings of ($0.53) per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $27.00 target price on the stock. The consensus estimate for Icosavax’s current full-year earnings is ($2.47) per share. Oppenheimer also issued estimates for Icosavax’s Q2 2023 earnings at ($0.57) EPS, Q3 2023 earnings at ($0.56) EPS, Q4 2023 earnings at ($0.63) EPS, FY2023 earnings at ($2.28) EPS, FY2024 earnings at ($2.06) EPS, FY2025 earnings at ($2.15) EPS and FY2027 earnings at $5.48 EPS.

Icosavax Trading Down 6.6 %

ICVX stock opened at $5.49 on Thursday. The company has a market capitalization of $227.40 million, a PE ratio of -2.38 and a beta of 0.44. Icosavax has a 12-month low of $2.28 and a 12-month high of $16.45. The business’s fifty day moving average price is $6.71 and its 200 day moving average price is $6.54.

Insider Activity at Icosavax

In related news, insider Douglas Holtzman sold 20,443 shares of the business’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $6.09, for a total value of $124,497.87. Following the sale, the insider now owns 290,054 shares in the company, valued at approximately $1,766,428.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Icosavax news, CEO Adam K. Simpson sold 7,506 shares of the company’s stock in a transaction dated Monday, February 13th. The stock was sold at an average price of $10.69, for a total transaction of $80,239.14. Following the sale, the chief executive officer now owns 245,041 shares in the company, valued at approximately $2,619,488.29. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Douglas Holtzman sold 20,443 shares of the company’s stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $6.09, for a total value of $124,497.87. Following the sale, the insider now owns 290,054 shares in the company, valued at approximately $1,766,428.86. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,295 shares of company stock worth $343,396. 39.09% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Icosavax

Large investors have recently bought and sold shares of the stock. Barclays PLC increased its holdings in Icosavax by 505.6% during the 4th quarter. Barclays PLC now owns 6,020 shares of the company’s stock worth $47,000 after purchasing an additional 5,026 shares during the period. Spire Wealth Management purchased a new stake in Icosavax during the 4th quarter worth about $84,000. Gladius Capital Management LP increased its holdings in Icosavax by 40.6% during the 4th quarter. Gladius Capital Management LP now owns 11,010 shares of the company’s stock worth $88,000 after purchasing an additional 3,182 shares during the period. American International Group Inc. increased its holdings in Icosavax by 68.9% during the 1st quarter. American International Group Inc. now owns 12,005 shares of the company’s stock worth $85,000 after purchasing an additional 4,896 shares during the period. Finally, MetLife Investment Management LLC purchased a new stake in Icosavax during the 4th quarter worth about $101,000. Hedge funds and other institutional investors own 80.54% of the company’s stock.

About Icosavax

(Get Rating)

Icosavax, Inc, a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial.

Earnings History and Estimates for Icosavax (NASDAQ:ICVX)

Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.